Clinically proven weight loss. Your choice of treatment.
Injectable or oral — both powered by tirzepatide, the most effective weight loss compound available. Prescribed by licensed providers and sent to a local pharmacy you choose.
Available treatments
Two FDA-approved options, both powered by tirzepatide. Your provider will recommend the best fit based on your health profile.
Zepbound®
tirzepatide injection
Dual GIP + GLP-1 receptor agonist
- Only dual-action GIP + GLP-1 approved for weight loss
- Once-weekly subcutaneous injection
- Gradual dose titration (2.5 mg → 15 mg)
- Pre-filled single-use pen — no mixing required
- Sent to a local pharmacy you choose
Adults with BMI ≥30, or BMI ≥27 with a weight-related condition
Once-weekly pre-filled pen
Foundayo™
tirzepatide oral
Dual GIP + GLP-1 receptor agonist
- Same active ingredient as Zepbound — in a daily pill
- No injections required
- Oral tablet taken once daily on an empty stomach
- Gradual dose escalation over several weeks
- Sent to a local pharmacy you choose
Adults with BMI ≥30, or BMI ≥27 with a weight-related condition
Once-daily tablet
How it works
From assessment to pharmacy pickup in four straightforward steps.
Join the waitlist
Enter your email to be notified as soon as we begin accepting patients.
Complete your assessment
A 5-minute health questionnaire reviewed by a licensed provider in your state.
Get your prescription
If approved, your provider sends the Rx to a local pharmacy you choose.
Pick up & ongoing care
Pick up your medication locally. Your provider manages dosing and follow-ups.
The science behind tirzepatide
Tirzepatide is the only FDA-approved weight loss compound that activates both GIP and GLP-1 receptors, delivering superior results to single-target GLP-1 medications.
maximum body weight reduction in SURMOUNT-1 trials
first and only GIP + GLP-1 receptor agonist for weight loss
injectable option — or once daily with the oral tablet
of clinical trial data supporting sustained weight loss
Am I eligible?
These medications are FDA-approved for adults who meet specific criteria. A licensed provider will confirm your eligibility.
Frequently asked questions
What is the difference between Zepbound and Foundayo?
Both contain tirzepatide, the same active ingredient made by Eli Lilly. Zepbound is a once-weekly injection using a pre-filled pen. Foundayo is a once-daily oral tablet. They have comparable clinical efficacy — the choice between them typically comes down to patient preference and provider recommendation.
Do I need to choose between injection and pill?
No — your licensed provider will discuss both options with you and recommend the best fit based on your health profile, lifestyle, and goals.
Why can’t I sign up right now?
We’re currently building our network of licensed providers. Join the waitlist and we’ll notify you as soon as we begin accepting patients.
Do I need insurance?
No — but if you have it, we’ll use it to get you the lowest medication cost. When you create your account, we verify your insurance upfront. If your plan covers Zepbound, we direct you to Eli Lilly’s Savings Card (as low as $25/fill). If not, we direct you to LillyDirect where self-pay pricing starts at $299/mo. Your Valitide subscription is the same either way.
How does pharmacy pickup work?
Once your provider approves your prescription, the Rx is sent electronically to a local pharmacy you select. You pick up your medication just like any other prescription.
How much weight can I expect to lose?
In clinical trials, participants on tirzepatide lost up to 22.5% of their body weight over 72 weeks. Individual results vary based on dosing, diet, exercise, and adherence.
Be first in line
We're onboarding licensed providers now. Join the waitlist and we'll reach out as soon as we're ready to accept patients.
No spam. Only launch updates and availability announcements.
Important Safety Information:Zepbound® and Foundayo™ (tirzepatide) are prescription medications and are not for everyone. Do not use if you or your family have ever had medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious side effects may include pancreatitis, gallbladder problems, kidney problems, and serious allergic reactions. Common side effects include nausea, diarrhea, decreased appetite, vomiting, constipation, and stomach pain. Zepbound® and Foundayo™ are registered trademarks of Eli Lilly and Company. Valitide is not affiliated with or endorsed by Eli Lilly and Company. All prescriptions are at the sole discretion of a licensed provider.